Friendly female doctor holding patient hand in office

Clinical Trials

Aldeyra is conducting Phase 3 clinical trials of reproxalap, our lead investigational RASP inhibitor, in dry eye disease and allergic conjunctivitis. In addition, we have begun enrollment in a Phase 3 clinical trial of ADX-2191 in proliferative vitreoretinopathy.

The links below will take you to information about these studies on clinicaltrials.gov. Medical professionals can also email for more information about clinical trial participation.

CLINICAL TRIAL

Phase 3 RENEW Trial for Dry Eye Disease

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap in Subjects With Dry Eye Disease

Learn More

CLINICAL TRIAL

Phase 3 INVIGORATE Trial for Allergic Conjunctivitis

A Randomized, Double-Masked, Crossover Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Learn More
Surgeons working on a patient
CLINICAL TRIAL

Phase 3 GUARD Trial for Proliferative Vitreoretinopathy

A Multi-Center, Randomized, Controlled, Adaptive Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 for the Prevention of Proliferative Vitreoretinopathy

Learn More